ReviewIndian journal of pediatrics2025
Management of Carbapenem Resistant Gram-Negative Infections.
Review in Indian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Expert insights: 10 key questions on managing common infections in cancer care in India.Ecancermedicalscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to increasing carbapenem usage, resistance to gram negative bacteria is steadily going up in India. Resistance is often enzyme-mediated and transmissible horizontally by plasmids. Use of invasive lines, procedures, prior antibiotic exposure, recent hospitalization, ICU stay, colonization and severity of illness are important risk factors for infections with these bacteria. Before starting therapy, it is important to distinguish colonization from true infection. Early targeted therapy using rapid diagnostic methods is important to ensure optimal outcomes. A growing body of literature recommends the use of novel beta lactam-beta lactamase inhibitors over polymyxins in the management of these infections. Treatment strategies for carbapenem resistant Enterobacterales differs from non-Enterobacterales and is discussed in detail in this review. Infection control and antimicrobial stewardship are crucial preventive measures to curb the emergence of further resistance.
Indexed as
Identifiers
40227352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.